





		Trimester			
Guidel	ine 1s	t 2no	d 3rd	l Post- partum	
who	<11.0	g/dL <11.0	g/dL <11.0 g	g/dL < 10 g/dl	L
CDC	<11.0	g/dL <10.5	g/dL <11.0 g	g/dL	
ACOG	<11.0	g/dL <10.5	g/dL <11.0 g	g/dL	














.




















<section-header><section-header><section-header><image><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item>








Risk of haemorrhage during childbirth in women with pre-existing anaemia. Women in Ghana with moderate-severe anaemia (Hb <10 gid), undergoing vaginal deliveries<sup>1</sup> "For every unit increase in Hb, the odds of developing primary PPH decreased 0.5791 times (95% CI 0.46-0.73)." oenegai and Mali, severe chroni aemia (<7 gidL) was significantly sociated with risk of PPH maternal intality (all delivery methods)<sup>4</sup> OR 3.14 (1.21-8.14) Women in Egypt with antepartum anae (Hb ≤11 mg/dL) who underwent vaginal deliveries Anaemic women in USA undergoing vaginal deliveries (Hb <9 g/dL)<sup>2</sup> OR 2.73 (1.43-5.23) OP 1 UK births<sup>3</sup> (all delivery methods) 
 UK births<sup>2</sup>
 Pre-pregnancy
 During pregnancy


 (all delivery
 Pre-pregnancy
 During pregnancy


 methods)
 anaemia
 and Hb <10.5 gkL</td>

 PPH >1500 mL
 OR 1.31 (0.35-4.95)
 OR 1.27 (0.84-1.92)


 PPH >500 mL
 OR 0.76 (0.24-2.43)
 OR 1.16 (0.83-1.60)
 OR 1.82 (1.00-3.32 OR 0.99 (0.72-1.35) ural Ugan da with m ring pregnancy (all Pro (FF7261) - the attempt of the second sec CI, confidence interval; Hb, haemoglobin; IDA, iron-deficiency anaemia; OR, odds ratio; PPH, postpartum haemorrhage





























Progressive iron depletion and deficiency					
Stage I: Iron depletion (NAID)	Serum iron – can be low Serum ferritin – low Iron stores – low or absent	Not anaemic No morphologic changes			
Stage II: Early iron deficiency	Serum iron – can be low Serum ferritin – low Iron stores – absent	Normocytic anaemia No morphologic changes			
Stage III: Advanced iron deficiency	Serum iron – can be low Serum ferritin – low Iron stores – absent	Increased RDW Microcytic hypochromic anaemia Tissue changes – glossitis, stomatitis, koilonychias, oesophageal webbing			
































43


## Screen ALL gravidas at high risk for iron deficiency • Previous diagnosis of iron deficiency


- Diabetes
- Smoking
   HIV infection
- Inflammatory bowel disease
- \* Multiparas, especially those with an interpregnancy interval <6 months
- History of abnormal uterine bleeding
- Body mass index (BMI) above or below the normal range
- Vegetarian or vegan diet
- Symptoms such as restless legs syndrome or pica, especially pagophagia (ice craving)
   Decreased access to health care, which may correlate with decreased screening for heavy menstrual bleeding and infections and reduced access to healthy foods


44



Hemoglobin level	No. of pregnant patients (% of all patients with a CBC test)	No. of pregnant patients with subsequent ferritin (% of anemia severity category
100-104 g/L	2014 (5.92)	447 (22.19)
90-99 g/L	1046 (3.07)	365 (34.89)
80-89 g/L	176 (0.52)	68 (38.64)
70-79 g/L	26 (0.08)	11 (42.31)
<70 g/L	6 (0.02)	4 (66.67)









 Absorption

 • Western diet: 10–20 mg of iron/day


 • Herne iron (meat, poultry, fish)

 • well absorbed (30%)

 • Inorganic iron (meat, vegetables)

 • poorly absorbed (<10%)</td>













M	aternal iron intake		*1
0	Material Construction (119 and 11) and 11 and 12 an	KAZAKHSTAN	ALL CONTRACTOR
	J et al. Br J Nutr. 2017 Mar: 117/61:882-871.		













• Design: A p	ragmatic randomised controlled clinical trial.	
•	ealth centres in Maputo, Mozambique.	
<ul> <li>Participant</li> </ul>	S: Pregnant women (218 years old; non-high-risk pregnancy) were randomly allocated to routine t) and selective iron (n=2142) groups.	•
<ul> <li>Interventio</li> </ul>	ns:	
<ul> <li>Selectiv</li> </ul>	group: 60 mg ferrous sulfate plus 400 µg folic acid/d a group: 1 mg of folic acid daily and haemoglobin (Hb) screening at each visit, with low Hb (cut-off 9 g/dL) ((120 mg+800 µg of folic acid daily) for a month.	
Outcome n	leasures:	
<ul> <li>Primary</li> </ul>	outcomes: preterm birth, low birth weight	
<ul> <li>Second death.</li> </ul>	rry outcomes: self-reported malaria, labour complications, caesarean section, perinatal death, woman's	


 Normal control of all control of the state of t





































Haemoglobin on Admission for Labor and Delivery Medical and an admission for Labor and Delivery Medical admission for Labor admission for Labor




## Conclusion

- No severe adverse reactions
   Overall mild adverse reactions lower with IV iron vs oral iron


- Effect size greatest in:
   studies from developing countries
   higher quality studies
   Studies with pretreatment Hb <= 9 g/dL
- Statistically significant improvement in mean Hb with IV iron that extended 2-6 weeks after treatment
   Different from previous meta-analyses, as only RCTs and no observational studies included
   Higher neonatal birthweight and neonatal ferritin in IV iron group


79





80


inatology 2019 (39):519-53















































Treatment of iron defic	iency in pregnancy			
IV Iron	not used in first trimester due to lack of s	afety data		
1st trimester	Iron deficiency only	Oral iron	Sensitive	
	Iron deficiency anaemia (Hb <11 g/dL)	Oral iron	Sensitive	
2 <sup>nd</sup> trimester	Iron deficiency only	Oral iron	Sensitive	
	Iron deficiency anaemia (Hb <10.5 g/dL)	IV iron	Sensitive	
3rd trimester	Iron deficiency only	IV iron	Critical	
	Iron deficiency anaemia (Hb <11 g/dL)	IV iron	Critical	
6-24 months of infancy	Iron deficiency	Oral iron	Critical	
If sever	e anaemia, poor response to oral iron or i treat with intravenous iron	ntolerance,		
reymann C, et al. J Perinst Med 2011;39:113-21;	IV iron treatment in pregnancy should be con cubweigh the potential risk for both the mother a before use during pregnancy, and IV iron should	nd the foetus. A careful i not be used during pre-	iskbenefit evaluation is required	
Auerbach M. Reprod Health 2018;15 (Suppl 1):96; Ferinject SmPC, February 2022				© Ven

